The march towards CFTR modulator access for all people with CF: The end of the beginning
- 22 January 2021
- journal article
- editorial
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (2), 185-187
- https://doi.org/10.1016/j.jcf.2021.01.005
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- CFTR modulator theratyping: Current status, gaps and future directionsJournal of Cystic Fibrosis, 2018
- Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delThe New England Journal of Medicine, 2017
- High-Throughput Screening for Readthrough Modulators of CFTR PTC MutationsSLAS Technology, 2017
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRThe New England Journal of Medicine, 2015
- Pricing for Orphan DrugsJAMA, 2013
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Proceedings of the National Academy of Sciences of the United States of America, 2011
- Targeting F508del-CFTR to develop rational new therapies for cystic fibrosisActa Pharmacologica Sinica, 2011
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proceedings of the National Academy of Sciences of the United States of America, 2009
- Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosisCell, 1993